Rheumatoid vasculitis: vanishing menace or target for new treatments?
Rheumatoid vasculitis is a rare but serious complication of rheumatoid arthritis. Herein we examine the pathophysiology, epidemiology, clinical diagnosis, and treatment of rheumatoid vasculitis. Seropositivity, specific HLA variations, and tobacco use are among the genetic and environmental predictors of rheumatoid vasculitis. Fortunately, recent reports have noted declines in the prevalence of rheumatoid vasculitis. Nevertheless, proper recognition of systemic manifestations may assist in pathologically confirming the diagnosis, determining the extent of disease, and guiding treatment. Contemporary treatment reports are discussed in the context of the ongoing debate regarding whether new agents may trigger, treat, or even prevent rheumatoid vasculitis. Evolving genetic, histopathologic, and immunologic studies partnered with ongoing clinical experience with biologics offer promise to inform future prevention and treatment of rheumatoid vasculitis.
Bartels
Christie M
CM
University of Wisconsin-Madison School of Medicine and Public Health, William S. Middleton Memorial Veterans Hospital-Madison, 2500 Overlook Terrace, Madison, WI 53705, USA. cb4@medicine.wisc.edu
Bridges
Alan J
AJ
D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D015995:Prevalence; D056653:Rheumatoid Vasculitis / Q000628:therapy*; D015996:Survival Rate
D007155:Immunologic Factors